Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Total Valuation
Oric Pharmaceuticals has a market cap or net worth of $878.66M. The enterprise value is $169.39M.
Market Cap$878.66M
Enterprise Value$169.39M
Share Statistics
Oric Pharmaceuticals has 85,224,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding85,224,190
Owned by Insiders17.56%
Owned by Institutions0.25%
Financial Efficiency
Oric Pharmaceuticals’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -57.32%.
Return on Equity (ROE)-0.53
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-57.32%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee0.00
Profits Per Employee-1.05M
Employee Count122
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oric Pharmaceuticals is -4.40. Oric Pharmaceuticals’s PEG ratio is -0.20.
PE Ratio-4.40
PS Ratio0.00
PB Ratio1.05
Price to Fair Value2.31
Price to FCF-3.02
Price to Operating Cash Flow-3.11
PEG Ratio-0.20
Income Statement
In the last 12 months, Oric Pharmaceuticals had revenue of 0.00 and earned -127.85M in profits. Earnings per share was -1.83.
Revenue0.00
Gross Profit0.00
Operating Income-142.90M
Pretax Income-127.85M
Net Income-127.85M
EBITDA-126.74M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -115.01M and capital expenditures -970.00K, giving a free cash flow of -115.98M billion.
Operating Cash Flow-115.01M
Free Cash Flow-115.98M
Free Cash Flow per Share-1.36
Dividends & Yields
Oric Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.65
52-Week Price Change34.97%
50-Day Moving Average7.14
200-Day Moving Average8.36
Relative Strength Index (RSI)66.10
Average Volume (3m)1.74M
Important Dates
Oric Pharmaceuticals upcoming earnings date is Aug 7, 2025, After Close (Confirmed).
Last Earnings DateMay 5, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Oric Pharmaceuticals as a current ratio of 10.56, with Debt / Equity ratio of 1.20%
Current Ratio10.56
Quick Ratio10.56
Debt to Market Cap0.00
Net Debt to EBITDA0.44
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oric Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oric Pharmaceuticals EV to EBITDA ratio is -4.00, with an EV/FCF ratio of -4.45.
EV to Sales0.00
EV to EBITDA-4.00
EV to Free Cash Flow-4.45
EV to Operating Cash Flow-4.50
Balance Sheet
Oric Pharmaceuticals has $203.72M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$203.72M billion.
Cash & Marketable Securities$203.72M
Total Debt$0.00
Net Cash-$203.72M
Net Cash Per Share-$2.39
Tangible Book Value Per Share$3.49
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oric Pharmaceuticals is $18.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.50
Price Target Upside82.27% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast7.15%